Contrasting Structure Therapeutics (NASDAQ:GPCR) and Alkermes (NASDAQ:ALKS)

Structure Therapeutics (NASDAQ:GPCR) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Structure Therapeutics and Alkermes, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	1	0	7	1	2.89
Alkermes	0	3	9	2	2.93

Structure Therapeutics presently has a consensus target price of $68.67, indicating a potential upside of 146.38%. Alkermes has a consensus target price of $42.00, indicating a potential upside of 35.57%. Given Structure Therapeutics’ higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Alkermes.

Profitability

This table compares Structure Therapeutics and Alkermes’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-21.31%	-20.34%
Alkermes	23.15%	24.86%	17.14%

Volatility & Risk

Structure Therapeutics has a beta of -1.65, meaning that its stock price is 265% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.

Insider and Institutional Ownership

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 5.6% of Structure Therapeutics shares are owned by insiders. Comparatively, 4.4% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Structure Therapeutics and Alkermes”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$122.53 million	($1.05)	-26.54
Alkermes	$1.51 billion	3.40	$367.07 million	$2.08	14.89

Alkermes has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Summary

Alkermes beats Structure Therapeutics on 12 of the 14 factors compared between the two stocks.

About Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.